Watchful Waiting (Surveillance) for Non-Hodgkin's Lymphoma

Skip to the navigation

Treatment Overview

Watchful waiting (surveillance) is a period in the treatment of some types of non-Hodgkin's lymphoma (NHL) in which you are not having treatment. It does not mean that your doctors are giving up or refusing to give you treatment.

What To Expect After Treatment

During this time, you will:

  • Receive periodic medical tests, including chest X-rays, CT scans, and blood tests, such as chemistry screens and complete blood counts (CBCs).
  • See your doctor on a regular basis.
  • Be told which symptoms to report to your doctor immediately.

Why It Is Done

Watchful waiting may be an option for you if:

  • Your lymphoma is slow-growing (indolent or low-grade).
  • Your lymphoma may be a kind that does not respond well to chemotherapy or radiation therapy in its current state.
  • You are living comfortably and do not have significant symptoms from your lymphoma.

How Well It Works

Watchful waiting is often as effective as other treatments for some types of non-Hodgkin's lymphoma (NHL). Some people with slow-growing NHL may live a long time without symptoms.

Risks

There do not seem to be any risks involved in watchful waiting for some types of NHL when you are being watched closely by your doctor. If your lymphoma changes, other treatments such as chemotherapy or radiation therapy may be used to control your disease.

What To Think About

Watchful waiting may be a good option if your lymphoma is not the type that can be cured with standard therapy, you are not having troublesome symptoms, and standard therapy is not likely to prolong your life.

Watchful waiting ends when one of the following occurs:

  • Symptoms develop.
  • Lymphoma tumor size increases.
  • Organs do not function normally.

Complete the special treatment information form (PDF)(What is a PDF document?) to help you understand this treatment.

Credits

ByHealthwise Staff

Primary Medical ReviewerAnne C. Poinier, MD - Internal Medicine

Specialist Medical ReviewerDouglas A. Stewart, MD - Medical Oncology

Current as ofMay 3, 2017